三阴性乳腺癌
乳腺癌
表观遗传学
医学
癌变
癌症研究
临床试验
肿瘤科
癌症
生物信息学
内科学
生物
基因
生物化学
作者
Cristina Maccallini,Alessandra Ammazzalorso,Barbara De Filippis,Marialuigia Fantacuzzi,Letizia Giampietro,Rosa Amoroso
出处
期刊:Pharmaceuticals
[Multidisciplinary Digital Publishing Institute]
日期:2022-05-26
卷期号:15 (6): 667-667
被引量:7
摘要
Triple negative breast cancer (TNBC) is an urgent as well as huge medical challenge, which is associated with poor prognosis and responsiveness to chemotherapies. Since epigenetic changes are highly implicated in TNBC tumorigenesis and development, inhibitors of histone deacetylases (HDACIs) could represent a promising therapeutic strategy. Although clinical trials involving single HDACIs showed disappointing results against TNBC, recent studies emphasize the high potential impact of HDACIs in controlling TNBC. In addition, encouraging results stem from new compounds designed to obtain isoform selectivity and/or polypharmacological HDAC approach. The present review provides a discussion of the HDACIs pharmacophoric models and of the structural modifications, leading to compounds with a potent activity against TNBC progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI